ADCT Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
19.2M
-7.7%
20.9M
-9.6%
23.1M
+40.4%
16.4M
-12.8%
18.8M
Cost of Revenue
2.3M
-35.0%
3.6M
+112.8%
1.7M
+41.3%
1.2M
+43.8%
836.0K
Gross Profit
16.9M
-2.0%
17.2M
-19.3%
21.4M
+40.3%
15.2M
-15.4%
18.0M
Operating Expenses
42.3M
-0.4%
42.5M
+8.2%
39.3M
-15.0%
46.2M
-25.7%
62.1M
R&D
17.4M
-12.6%
19.9M
+9.3%
18.2M
-32.2%
26.8M
-10.9%
30.1M
SG&A
22.3M
-1.5%
22.6M
+5.4%
21.4M
+12.8%
19.0M
+0.2%
19.0M
Operating Income
-25414000
-0.7%
-25245000
-40.9%
-17919000
+42.1%
-30969000
+29.9%
-44147000
EBITDA
-22740000
+9.9%
-25245000
-38.2%
-18267000
+40.3%
-30591000
+1.5%
-31056000
Net Income
-16565000
+49.8%
-32968000
-414.4%
-6409000
+84.4%
-40966000
+27.7%
-56646000
EPS (Basic)
$-0.11
+47.6%
$-0.21
-425.0%
$-0.04
+86.7%
$-0.30
+40.0%
$-0.50
EPS (Diluted)
$-0.11
+47.6%
$-0.21
-425.0%
$-0.04
+86.7%
$-0.30
+40.0%
$-0.50
Shares (Diluted)
155.0M
+0.6%
154.1M
+2.2%
150.9M
+10.6%
136.4M
+20.0%
113.7M
ADC Therapeutics SA (ADCT) โ€” Financials